Note: Immuneering Corp. is a preclinical biopharma company. From the prospectus: “We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a […]

We intend to focus our initial business combination search in the ecommerce sector, specifically on companies offering Software-as-a-Service (“SaaS”) products and services to enterprise customers globally. We currently intend to focus on opportunities that capitalize on the expertise and ability of our management team, particularly our Chairman, M. Blair Garrou; our President and Chief Executive […]

We are a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. Our proprietary RxSight Light Adjustable Lens system (“RxSight system”), comprised of our RxSight Light Adjustable Lens (“LAL”), RxSight Light Delivery Device (“LDD”) and accessories, is the first and only commercially available intraocular lens (“IOL”) technology that enables doctors […]

We are a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with […]

At Omega Therapeutics, our goal is to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. Our pioneering OMEGA Epigenomic Programming platform is designed to coopt nature’s universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. We have deciphered the […]

Our efforts to identify a prospective target business will not be limited to a particular industry or geographic location, although we currently intend to focus on opportunities in Asia. (Incorporated in the British Virgin Islands)  (Note: 8i Acquisition 2 Corp. priced its SPAC IPO on Monday morning, Nov. 22, 2021, in line with the terms […]

We intend to capitalize on our management team’s background and experience to identify promising opportunities in the life sciences sector. We are offering Class A ordinary shares. (This is NOT a unit offering; most blank-check or SPAC IPOs are unit offerings.) Our CEO is Steven Kafka, Ph.D., a managing partner at Section 32, a venture […]

Alpha Partners Technology Merger Corp. intends to merge and partner with a technology business. (Incorporated in the Cayman Islands) We will focus on technology businesses that address large and acute market needs or pain-points via the application of software or technology-enabled business models. We intend to pay particularly close attention to businesses powered by long-term secular […]

We intend to leverage our deep financial and banking experience, extensive brokerage and trading background and large network of industry contacts in order to pursue opportunities with high-quality, growth companies in our focus sectors of financial services, and FinTech and technology. We are seeking a business with a strong technology offering, in a disruptive vertical, […]

Context Therapeutics® is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. Profound advancements in oncology drug development have expanded the treatment options available to women with cancer, yet therapeutic resistance and relapse continue to limit the efficacy and duration of such treatments. Collectively, our founders and management team have decades […]